9441 related articles for article (PubMed ID: 17160167)
41. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
[TBL] [Abstract][Full Text] [Related]
42. [Clinical significance of serum S-100B protein in severe cerebral injury].
Hu DL; Liu XH; Yu XL; Guo HM; Guo B; Shi Y; Zhuang HL; Shi P
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Apr; 16(4):221-2. PubMed ID: 15068714
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
44. Monitoring malignant melanoma with the S-100B tumour marker.
Bonfrer JM; Korse CM
Recent Results Cancer Res; 2001; 158():149-57. PubMed ID: 11092042
[TBL] [Abstract][Full Text] [Related]
45. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
46. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
47. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
48. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
49. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
50. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.
Bonfrer JM; Korse CM; Nieweg OE; Rankin EM
Br J Cancer; 1998 Jun; 77(12):2210-4. PubMed ID: 9649135
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of serum S-100B in malignant melanoma.
Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
[TBL] [Abstract][Full Text] [Related]
52. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
Strobel K; Dummer R; Steinert HC; Conzett KB; Schad K; Lago MP; Soyka JD; Veit-Haibach P; Seifert B; Kalff V
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1786-95. PubMed ID: 18458901
[TBL] [Abstract][Full Text] [Related]
54. [S-100B protein elevation in patients with the acute coronary syndrome after resuscitation is a predictor of adverse neurological prognosis].
Helánová K; Pařenica J; Jarkovský J; Dostálová L; Littnerová S; Klabenešová I; Cermáková Z; Lokaj P; Kala P; Poloczek M; Toman O; Gimunová O; Maláska J; Spinar J
Vnitr Lek; 2012 Apr; 58(4):266-72. PubMed ID: 22559799
[TBL] [Abstract][Full Text] [Related]
55. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
Strobel K; Skalsky J; Kalff V; Baumann K; Seifert B; Joller-Jemelka H; Dummer R; Steinert HC
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1366-75. PubMed ID: 17390135
[TBL] [Abstract][Full Text] [Related]
56. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
57. Elevated serum S-100B levels in children with temporal lobe epilepsy.
Calik M; Abuhandan M; Sonmezler A; Kandemır H; Oz I; Taskin A; Selek S; Iscan A
Seizure; 2013 Mar; 22(2):99-102. PubMed ID: 23146618
[TBL] [Abstract][Full Text] [Related]
58. S-100B concentration is not related to neurocognitive performance in the first month after mild traumatic brain injury.
Stapert S; de Kruijk J; Houx P; Menheere P; Twijnstra A; Jolles J
Eur Neurol; 2005; 53(1):22-6. PubMed ID: 15677870
[TBL] [Abstract][Full Text] [Related]
59. Early S-100B serum level correlates to quality of life in patients after severe head injury.
Woertgen C; Rothoerl RD; Brawanski A
Brain Inj; 2002 Sep; 16(9):807-16. PubMed ID: 12217206
[TBL] [Abstract][Full Text] [Related]
60. Comparison of three assays for quantifying S-100B in serum.
Erickson JA; Grenache DG
Clin Chim Acta; 2011 Nov; 412(23-24):2122-7. PubMed ID: 21824469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
